KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Royalty Pharma (RPRX) Minority Interest (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Minority Interest for 7 consecutive years, with $3.2 billion as the latest value for Q4 2025.

  • Quarterly Minority Interest fell 4.65% to $3.2 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.2 billion through Dec 2025, down 4.65% year-over-year, with the annual reading at $3.2 billion for FY2025, 4.65% down from the prior year.
  • Minority Interest hit $3.2 billion in Q4 2025 for Royalty Pharma, up from $3.2 billion in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of $5.0 billion in Q1 2021 to a low of $3.1 billion in Q1 2025.
  • Historically, Minority Interest has averaged $3.8 billion across 5 years, with a median of $3.5 billion in 2023.
  • Biggest five-year swings in Minority Interest: fell 19.38% in 2023 and later decreased 1.67% in 2024.
  • Year by year, Minority Interest stood at $4.5 billion in 2021, then dropped by 12.85% to $3.9 billion in 2022, then fell by 8.71% to $3.6 billion in 2023, then fell by 4.55% to $3.4 billion in 2024, then decreased by 4.65% to $3.2 billion in 2025.
  • Business Quant data shows Minority Interest for RPRX at $3.2 billion in Q4 2025, $3.2 billion in Q3 2025, and $3.2 billion in Q2 2025.